Yuan Dong Bio (SHA: 688513): Melogabalin Benzenesulfonate Tablets Received Drug Registration Certificate

Gelonghui, June 15 — Yuandong Bio (SHA: 688513) announced that the company recently received a Drug Registration Certificate for Melogabalin Benzenesulfonate Tablets issued by the National Medical Products Administration. The active ingredient of this product is melogabalin benzenesulfonate, indicated for the treatment of diabetic peripheral neuropathic pain in adults. It is classified as a Category B drug under the National Reimbursement Drug List for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance (2025 Edition).

Gelonghui FinanceJun 15 17:45

YuanDong Bio (688513.SH): Repurchased 44,300 Shares of the Company's Stock for the First Time

Gelonghui, June 5 — Yuandong Bio (SHA: 688513) announced that on June 5, 2026, the company repurchased 44,258 of its shares for the first time via centralized bidding transactions, representing 0.0251% of the company's total share capital. The highest purchase price was RMB 46.89 per share and the lowest was RMB 46.46 per share, with a total transaction amount of RMB 2,070,868.44 (excluding stamp duty, brokerage commissions, and other transaction fees).

Gelonghui FinanceJun 5 17:29

Express News | Yuandong Bio: Plans to repurchase shares at a cost of RMB 50 million to RMB 100 million.

BreakingsJun 3 19:14

Yuan Dong Bio (688513.SH) proposes to launch a restricted stock incentive plan for 2026.

Yuan Dong Bio (SHA: 688513) disclosed a draft of its 2026 Restricted Stock Incentive Plan, proposing to grant 800,000 shares of restricted stock to incentive recipients, representing approximately 0.45% of the company's total share capital as of the announcement date of the draft plan. Of this, 650,000 shares are designated for initial grant to a total of 16 incentive recipients, with a grant price (including reserved shares) of RMB 32.30 per share.

Zhitong FinanceMay 28 18:49

YuanDong Bio (688513.SH): Vitamin K1 Injection Receives Drug Registration Certificate

Gelonghui, May 22 — Eastbiopharm (SHA: 688513) announced that the company recently received a Drug Registration Certificate issued by the National Medical Products Administration. The active ingredient of this product is vitamin K1, indicated for the treatment of vitamin K deficiency-related bleeding and for the prevention of vitamin K deficiency in cases where nutritional supplementation is not feasible. This includes: (1) prevention of vitamin K deficiency in patients at risk of vitamin K deficiency when the INR exceeds the upper limit of the normal range; and (2) treatment of patients with vitamin K deficiency-related bleeding and an INR ≥ 5. Vitamin K deficiency-related bleeding may result from vitamin K deficiency or the use of

Gelonghui FinanceMay 22 17:30

Express News | Yuandong Bio: There are no matters that should be disclosed but have not been disclosed.

BreakingsMay 19 18:34